Svati Shah, M.D., MHS, has been appointed director of the Duke Precision Genomics Collaboratory and associate dean of genomics.
Bruce Donald’s company, Gavilán Biodesign, was featured as one of eight Duke start-up investments at the first Duke Venture Day earlier this month. This event showcased therapeutic innovations currently coming out of Duke. Gavilan Biodesign was recently selected as one of 11 early-stage biotech companies at the Silicon Valley biotech accelerator, IndieBio. Their technology combines state of the art physics-based modeling with a unique high accuracy AI platform to computationally screen trillions of molecules in order to find therapeutics that can overcome resistance.
Story adopted from an article originally posted on the Office of Licensing and Ventures on May 9, 2019.